Mosaic ImmunoEngineering (OTCMKTS:CPMV) Announces Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMV) issued its quarterly earnings data on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.

Mosaic ImmunoEngineering Price Performance

Shares of OTCMKTS CPMV remained flat at $0.06 during midday trading on Friday. 817 shares of the stock were exchanged, compared to its average volume of 1,073. Mosaic ImmunoEngineering has a 52 week low of $0.05 and a 52 week high of $1.05. The stock has a market capitalization of $441,762.00, a P/E ratio of -0.68 and a beta of -0.82. The business’s 50 day moving average is $0.59 and its 200-day moving average is $0.60.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.